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Abstract
Aims/hypothesis Genetically engineered human beta cell lines
provide a novel source of human beta cells to study metabolism,
pharmacology and beta cell replacement therapy. Since the im-
mune system is essentially involved in beta cell destruction in
type 1 diabetes and after beta cell transplantation, we investigated
the interaction of human beta cell lineswith the immune system to
resolve their potential for immune intervention protocol studies.
Methods Human pancreatic beta cell lines (EndoC-βH1 and
ECi50) generated by targeted oncogenesis in fetal pancreas
were assessed for viability after innate and adaptive immune
challenges. Beta cell lines were pre-conditioned with T helper
type 1 (Th1) cytokines or high glucose to mimic inflammatory
and hyperglycaemia-stressed conditions. Beta cells were then
co-cultured with auto- and alloreactive cytotoxic T cells
(CTL), natural killer (NK) cells, supernatant fraction from
activated autoreactive Th1 cells, or alloantibodies in the pres-
ence of complement or effector cells.
Results Low HLA expression protected human beta cell lines
from adaptive immune destruction, but it was associated with
direct killing by activated NK cells. Autoreactive Th1 cell
inflammation, rather than glucose stress, induced increased
beta cell apoptosis and upregulation of HLA, increasing beta
cell vulnerability to killing by auto- and alloreactive CTL and
alloreactive antibodies.
Conclusions/interpretation We demonstrate that genetically
engineered human beta cell lines can be used in vitro to assess
diverse immune responses that may be involved in the patho-
genesis of type 1 diabetes in humans and beta cell transplanta-
tion, enabling preclinical evaluation of novel immune interven-
tion strategies protecting beta cells from immune destruction.
Keywords Adaptive immunity . Beta cell . Innate immunity .
Transplantation
Abbreviations
B-LCL B-lymphoblastoid cell lines
CMV Cytomegalovirus
CTL Cytotoxic T cells
EF1α Elongation factor 1-alpha
MFI Mean fluorescence intensity
MSC Mesenchymal stromal cell
NK Natural killer
PBL Peripheral blood lymphocytes
PBMC Peripheral blood mononuclear cells
PPI Preproinsulin
PTEC Primary tubular epithelial cell
Th1 T helper type 1
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Beta cell replacement by pancreas or islet transplantation is
currently the only curative treatment for established type 1
diabetes. Insulin independence using current islet transplanta-
tion protocols is often temporary despite aggressive immune
suppression. Both innate and adaptive immune responses
threaten transplanted beta cells and need to be controlled by
immune suppression [1–3].More effective and less toxic strat-
egies are required to make beta cell transplantation affordable
to more patients.
Knowledge of interactions of human beta cells with the
immune system has been largely derived from studies on iso-
lated islets from pancreas donors. Access to such preparations
for scientific purposes is limited; furthermore, variations be-
tween islet preparations and their composition, including a
range of other cell types, hinder beta cell-specific studies.
Human genetically engineered beta cell lines provide a novel
tool to study functional human beta cells in standardised as-
says [4]. Thus, beta cell lines may help to identify immune
responses relevant to human type 1 diabetes and beta cell
transplantation.
We investigated innate and adaptive immune responses
potentially harmful to beta cells in the pathogenesis of
type 1 diabetes and beta cell transplantation on genetically
engineered human beta cell lines to assess their potential for
preclinical evaluation of novel immune intervention
strategies.
Methods
Two human fetal beta cell lines with similar function
(EndoC-βH1 and ECi50; Endocells, Paris, France) were gen-
erated and maintained as previously reported [4]. To mimic
inflammation or hyperglycaemia, beta cell lines were preincu-
bated overnight with IFNγ (1,000 U/ml; R&D Systems,
Abingdon, UK) or glucose 20 mmol/l. Introduction of EF1α
promoter-drivenHLA-A*02:01 into beta cell line EndoC-βH1
was achieved by lentiviral transduction [5]. HLA genotyping
was carried out at the Eurotransplant Reference Laboratory,
Leiden University Medical Center, Leiden, the Netherlands.
Informed consent and approval of the institutional review
board was obtained for the generation of human cell lines and
antibodies and was carried out in accordance with the 2008
revised principles of the Declaration of Helsinki.
Peripheral blood mononuclear cells (PBMC) were separat-
ed from full blood or buffy coats (for natural killer [NK] cells
and lymphocytes) by Ficoll-Hypaque density gradient. Pe-
ripheral blood lymphocytes (PBL) were separated by CD14
depletion of PBMCwith CD14MicroBeads (Miltenyi Biotec,
Auburn, CA,USA). NK cells were purified fromPBMCusing
the human NK Cell Isolation Kit (Miltenyi Biotech, Leiden,
the Netherlands), cultured and activated with IL-15 as de-
scribed [6]. Details about generation and maintenance of spe-
cific T cell clones, immortalised human primary tubular epi-
thelial cells (PTEC), HeLa, Epstein–Barr virus-transformed B
lymphocytes, mesenchymal stromal cells (MSC) and human
monoclonal antibodies recognising HLA have been previous-
ly published [7–11].
Beta cell-specific T helper (Th) cell supernatant fraction was
harvested from 3 day cultures of autoreactive Th1 clone 1c6
incubated with PBMC and preincubated with or without anti-
gen [12]. Supernatant fraction was stored at −80°C until use.
Cellular cytotoxicity was assessed by chromium re-
lease of 51Cr-labelled beta cell lines. Complement-
dependent cytotoxicity was measured by flow cytometry of
beta cell lines after incubation with human HLA-specific an-
tibodies and rabbit complement. Cytokine-driven beta cell
death was measured by propidium iodide staining and flow
cytometry after 48 h culture in Th1 cell supernatant fraction or
50 U/ml IL-1β, 1,000 U/ml IFNγ and 1,000 U/ml TNF-
supplemented medium. Cell surface antigen expression was
assessed by flow cytometry.
Experiments were not blinded. Experiments were excluded
if positive controls did not respond or with responding nega-
tive controls. Mycoplasma infection was excluded for all cell
lines at regular intervals.
Data are represented as mean and SD unless stated other-
wise. Statistics represent linear regression for titrated experi-
ments and Student’s t test for binary outcomes. GraphPad
Prism 6.0 (GraphPad Software, La Jolla, CA, USA) was used
to create graphs and perform analysis. Further details are giv-
en in the electronic supplementary material (ESM methods).
Results
Cytokine-mediated effects on beta cells
Two human beta cell lines (EndoC-βH1 and ECi50) were
selected for immunological analysis. Cells were genotyped
as HLA-A*33:03, A*68:01 (EndoC-βH1) and HLA-
A*02:02, A*68:01 (ECi50). HLA class I expression on
EndoC-βH1 was slightly lower than on ECi50 (geo-mean
fluorescence intensity [MFI] 21 vs 59), and much lower than
HLA express ion on var ious non-be ta ce l l l ines
(B-lymphoblastoid cell lines [B-LCL]: MFI 2146; MSC:
MFI 1299; PTEC: MFI 479; HeLa: MFI 481). HLA class I
expression could be upregulated by IFNγ (sixfold on ECi50,
ninefold on EndoC-βH1), while HLA class II expression
remained absent (Fig. 1a, c).
To assess the influence of autoimmune inflammation on
beta cell lines, cells were cultured in 3 day culture supernatant
fraction of activated islet autoreactive Th1 cells containing
IL-1β (16 pg/ml), IL-13 (113 pg/ml), IL-17 (36 pg/ml), IFNγ
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(1,000 pg/ml) and TNF (18 pg/ml) for 48 h. Supernatant frac-
tion of activated Tcells increased HLA class I, but not class II,
expression, similar to incubation with IFNγ (Fig. 1b).
Supernatant fraction of activated T cells increased beta cell
death from 46±5% to 70±2% (p<0.0001; n=3) for
EndoC-βH1, and from 36±6% to 59±5% (p<0.0001; n=3)
for ECi50. Comparably, incubation with mixed cytokines
(IFNγ 1,000 U/ml, TNF 1,000 U/ml and IL-1β 50 U/ml)
increased beta cell death from 22 ± 6% to 40 ± 8%
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Fig. 1 (a–c) HLA class I and class II expression was measured in beta
cell lines EndoC-βH1 and ECi50 and compared with other cell lines.
HLA expression was stimulated (dashed line) through incubation with
supernatant fraction (Sup.) of a beta cell-specific Th1 cell response or
inflammatory cytokine IFNγ; isotype controls are shown in light grey.
(d–f) Expression of complement inhibitory receptors CD46, CD55 and
CD59 on beta cell lines compared with other cell lines. (g–i) Cellular
cytotoxic responses to beta cell lines tested in chromium release assays.
(g) Alloreactive (HLA-A2-specific) CTLs vs beta cells expressing HLA-
A2 (black lines and symbols) or not expressing HLA-A2 (grey lines and
symbols). Unconditioned beta cells (solid black/grey lines and symbols)
were compared with HLA upregulated beta cells by IFNγ (solid black/
grey lines and white symbols) and glucose-stimulated beta cells (dashed
lines and black/grey symbols). (h) Autoreactive PPI-specific CTLs vs
HLA-A*02:01-transduced beta cells presenting peptide from endoge-
nously produced insulin (black symbols) or presenting exogenous loaded
peptide (white symbols), and mock transduced cells, in the presence of
exogenous peptide (dashed line). (i) Activated NK cells vs EndoC-βH1
(circles) and ECi50 (squares). Unconditioned beta cells (black lines and
symbols) were compared with HLA upregulated cells (solid lines and
white symbols) and glucose-stimulated cells (dashed lines and black sym-
bols). (j–l) Alloreactive antibodies, specific (solid lines) or non-specific
(dashed lines), for EndoC-βH1 HLA-induced lysis by (j) NK cells and
(k) PBL, and (l) through complement-dependent cytotoxicity without
(black symbols) or after (white symbols) HLA upregulation by IFNγ.
Data are presented as mean and SD; panels show representative experi-
ments. x-axes are plotted on logarithmic scales
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8% (p=0.0002; n=4) for ECi50. This resembles the effect
described on islets [2]. Individual cytokines did not induce
apoptosis.
Cell-mediated cytotoxicity
Destruction of beta cells by autoreactive cytotoxic T cells
(CTL) is the hallmark of type 1 diabetes. We therefore inves-
tigated autoreactive preproinsulin (PPI)-specific CTL re-
sponses to endogenous expression of beta cell antigens by
the cell lines. Since our effector T cell clones are HLA-A2
(*02:01)-restricted and the beta cell lines were lacking HLA-
A2, expression had to be introduced. Beta cell line
EndoC-βH1 was transduced with HLA-A*02:01 under the
elongation factor 1-alpha (EF1α) promotor. After passaging,
the generated line contained 39% HLA-A2-positive cells and
was stable for at least 12 passages. Expression of transduced
HLA-A*02:01 was MFI 118 and was unaffected by IFNγ.
Overnight incubation of the HLA-A2-transduced beta cell
line with PPI-specific cytotoxic T cells resulted in beta cell
cytolysis up to 34±3% (p<0.0001 for intercept; n=4) without
adding exogenous PPI peptide epitope, corresponding toHLA-
A2 expressing cell frequency (Fig. 1h). Pulsing of the trans-
duced beta cell with exogenous cytomegalovirus (CMV) pep-
tide epitope (mimicking CMV infection) resulted in killing by
CMV-specific CTLs with similar efficacy (data not shown).
Alloreactive CTLs can cause beta cell allograft rejection
after transplantation. Thus, beta cells were tested against
HLA-A*02:02-specific alloreactive CTLs. A beta cell line nat-
urally expressingHLA-A*02:02was killed (up to 66±5%) in a
4 h cytotoxicity assay only if HLAwas upregulated by IFNγ
(p=0.005 for intercept; n=3). Hyperglycaemic (>25 mmol/l
glucose) preincubation did not affect killing by alloreactive
CTLs (Fig. 1g). Specific recognition of beta cell lines by
alloreactive CTLs after HLA upregulation was verified by
expression of the cytolytic degranulation marker CD107a on
responding CTLs (data not shown).
Low HLA expression by the beta cell lines may render
these cells susceptible to NK cell reactivity. Indeed, acti-
vated NK cells killed beta cell line EndoC-βH1, which
expresses relatively less HLA more efficiently than ECi50
(up to 47±4% and 28±0%, respectively; p=0.016 for
slope; n=2). HLA upregulation reduced killing to 38±
2% (p=0.002 for intercept) for EndoC-βH1 and 11±1%
(p=0.0003 for slope) for ECi50 (Fig. 1i). Hyperglycaemia
did not influence NK cell killing of beta cell lines. Results
were corroborated by a CD107a degranulation assay (data
not shown).
Antibody- and complement-mediated killing
Antibodies recognising HLA can lead to acute rejection of
transplants through activation of immune cells or comple-
ment. Low HLA expression protected from antibody-
dependent cellular cytotoxicity by PBL or purified NK
cells. Yet, HLA upregulation increased killing through
alloreactive antibodies (for EndoC-βH1 up to 38±7%
through NK cells [p=0.002 for intercept; Fig. 1j]; and
up to 49 ± 6% through PBL [p< 0.0001 for slope;
Fig. 1k]). Complement inhibitory receptors generally pre-
vent direct complement activation, and beta cell lines
expressed CD59 and CD46, but not CD55 (Fig. 1d–f).
Beta cell lines were thereby protected from killing by
human serum complement.
To assess their killing potential, alloantibodies were titrated
in standard clinical cross-match assays using rabbit comple-
ment. Specific alloreactive antibodies induced >80%
complement-dependent cytotoxicity of beta cell lines upon
upregulation of HLA by IFNγ, whereas alloantibodies direct-
ed to HLA not expressed by the human beta cell lines had no
such effect (p=0.006 for slope) (Fig. 1l).
Table 1 Overview of results
Interaction with immune system Conditioning of beta-cell lines
Resting Inflammatory cytokines Glucose challenge
HLA expression Lower than other tissue cell lines Increased




Autoreactive Th cell supernatant Moderate apoptosis NA Moderate apoptosis
Autoreactive CTL recognition and killing Proinsulin-specific killing NA Proinsulin-specific killing






NK cell recognition and killing Recognition and differential killing Decreased killing Recognition and differential killing
ADCC No killing with HLA antibodies Concentration-dependent killing ND
CDC No killing with HLA antibodies Concentration-dependent killing ND
ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; NA, not applicable; ND, no data
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Discussion
We investigated immune responses to human beta cell lines
that may be relevant for diabetes pathogenesis and beta cell
transplantation, demonstrating the relevance of these beta cell
lines for preclinical studies on immune intervention strategies
(Table 1).
Studies of type 1 diabetic pancreases suggest that
autoreactive cytotoxic T cells are highly efficient killers of
beta cells [13]. We confirm that autoreactive T cell clone
1E6 can efficiently kill the beta cell lines that were HLA
compatible, which substantiates that these beta cell lines can
process and present PPI15–24 epitope from endogenously pro-
duced PPI to the immune system. This establishes these cell
lines as bona fide beta cells in terms of their susceptibility to
diabetogenic autoimmune reactions.
Alloreactive responses may be detrimental for transplanted
beta cells too.We show that beta cell lines become sensitive to
killing by donor-specific alloreactive CTLs or alloantibodies
if HLA is upregulated by inflammation. At the same time, low
HLA expression left unstimulated beta cell lines vulnerable to
activated NK cells. These data support clinical observations
that suppressing early inflammation may be as important for
transplant success as immunosuppression targeting adaptive
immunity.
Whether normal human beta cells express equally low
HLA remains unknown, since HLA expression by human beta
cells purified from isolated islets is difficult to quantify. How-
ever, HLA class I is markedly upregulated in pathogenic con-
ditions including insulitis in islets of type 1 diabetic patients
[13]. We confirm that supernatant fraction of autoreactive T
cells from a patient with type 1 diabetes responding to islet
antigen can upregulate HLA on beta cell line cells. Moreover,
these supernatant fractions increased beta cell death, similar to
previously described inflammatory cytokines [2].
In conclusion, we demonstrate that genetically engineered
human beta cell lines can be used in vitro to assess diverse
immune responses that may be involved in the pathogenesis of
type 1 diabetes in humans and in beta cell transplantation. This
enables human preclinical evaluation of novel immune inter-
vention strategies protecting beta cells.
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